Investors Back iOmx’s Focus On Tumor Immune Evasion
Developing Anti-Immune Evasion Platform
The German biopharmaceutical company has been around since 2016, but now has the funding to bring its first candidate into clinical trials by late 2022
You may also be interested in...
MIG Capital’s Matthias Kromayer looks back at the huge success of its long-term backing of BioNTech and discusses the group’s next big life sciences investments, but warns that realism and hard work are needed to achieve another breakthrough.
Novartis is playing catch-up in PD-1 inhibitors but could soon claim a best-in-class competitor in first-line esophageal cancer.
The UK biotech looks to have reached the end of the road, despite some encouraging signs from its microbiome-based pipeline.